EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY 4.0

Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial

Lars Fransecky, Walter Fiedler, Christoph Röllig, Tim Sauer, Simon Raffel, Winfried Alsdorf, Lisa Heberling, Britta Steer, Karin Huber, Tim Versteegen, Lea Spory, Dorothee Deckbar und 9 weitere

Annals of Hematology · 2026

DOI: 10.1007/s00277-026-06883-8 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Annals of Hematology, 2026. Verfasst von Lars Fransecky und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. lars.fransecky@uksh.de. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Antibodies, Bispecific, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Schleswig-Holstein - Campus Kiel.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prognosis of adult patients with relapsed/refractory (r/r) or measurable residual disease (MRD)–positive B-precursor acute lymphoblastic leukemia (B-ALL) remains poor. Blinatumomab induces complete remissions (CR) and MRD negativity in a subset of patients, yet overall survival remains limited. As BCL2 overexpression contributes to leukemic cell survival and therapy resistance, combining Blinatumomab with the BCL2 inhibitor Venetoclax may enhance therapeutic efficacy. The GMALL-BLIVEN (NCT05182385) phase I multicenter trial evaluated the safety and feasibility of Venetoclax plus Blinatumomab in adults with CD19⁺, Philadelphia chromosome–negative r/r or MRD-positive B-ALL. Dose escalation followed a 3 + 3 design across three Venetoclax dose levels (DL-1: 400 mg; DL-2: 600 mg; DL-3: 800 mg) administered from day − 7 to day 42, with Blinatumomab given per label. The primary endpoint was determination of the maximum tolerated dose (MTD); key secondary endpoint was achievement of molecular complete remission (MOL-CR) by centralized IG/TR MRD assessment (sensitivity ≥ 10⁻⁴). Nine patients (median age 52 years, range 22–71) were enrolled across four German centers: four with r/r B-ALL and five with MRD-positive disease. Molecular subtypes included ZNF384-rearranged (n = 2), BCR::ABL1-like (n = 2), CEBP-rearranged (n = 1), hypodiploidy (n = 1), B-ALL NOS (n = 2), and KMT2A-rearranged (n = 1). No dose-limiting toxicities were observed, and the MTD was not reached. Treatment-emergent grade ≥ III toxicities included neutropenia, febrile neutropenia, cytokine release syndrome, and ICANS; no 30- or 60-day mortality occurred. Six patients completed two full cycles without treatment interruptions. The recommended phase II dose (RP2D) was established as Venetoclax 800 mg daily plus standard-dose Blinatumomab. All nine patients were evaluable for response. Among r/r B-ALL, responses included PR ( n = 1), CR ( n = 1), and PD ( n = 2). Among MRD-positive patients, 4/5 achieved MOL-CR. Four patients were successfully bridged to allogeneic stem cell transplantation. After a median follow-up of 17.8 months, median overall survival was 15.0 months (r/r: 6.6 months; MRD-positive: 16.9 months). Non-responders were enriched for adverse molecular subtypes (BCR::ABL1-like and hypodiploid B-ALL). Venetoclax combined with Blinatumomab is safe and feasible in adults with r/r or MRD-positive B-ALL, without increased rates of CRS or neurotoxicity compared with Blinatumomab alone. High rates of MRD clearance were observed in MRD-positive patients. The phase II portion of GMALL-BLIVEN is ongoing at the RP2D of Venetoclax 800 mg daily.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bridged Bicyclo Compounds, HeterocyclicSulfonamidesAntibodies, BispecificPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleAdultNeoplasm, ResidualMiddle AgedMaleAgedRecurrencePhiladelphia ChromosomeYoung Adult

Stichwörter der Autor:innen

Acute leukemiaAcute lymphoblastic leukemia (ALL)BH3 mimeticsBispecific antibodyBlinatumomabMeasurable residual diseaseVenetoclax

Substanzen

blinatumomabBridged Bicyclo Compounds, HeterocyclicvenetoclaxSulfonamidesAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. lars.fransecky@uksh.de.
  • University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany. lars.fransecky@uksh.de.
  • Department of Oncology and Hematology with Section Pneumology, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg, Hamburg, Germany.
  • Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
  • Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Förderung

  • Universitätsklinikum Schleswig-Holstein - Campus Kiel

Zitieren

APA

Fransecky, L., Fiedler, W., Röllig, C., Sauer, T., Raffel, S., Alsdorf, W., Heberling, L., Steer, B., Huber, K., Versteegen, T., Spory, L., Deckbar, D., Reiser, L., Bendig, S., Bastian, L., Bozzetti, C., Beder, T., Neumann, M., Brüggemann, M., …, & Baldus, C. (2026). Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial. Annals of Hematology. https://doi.org/10.1007/s00277-026-06883-8

Vancouver

Fransecky L, Fiedler W, Röllig C, Sauer T, Raffel S, Alsdorf W, et al. Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial. Annals of Hematology. 2026. doi:10.1007/s00277-026-06883-8

BibTeX
@article{Fransecky2026,
  author = {Fransecky, Lars and Fiedler, Walter and Röllig, Christoph and Sauer, Tim and Raffel, Simon and Alsdorf, Winfried and Heberling, Lisa and Steer, Britta and Huber, Karin and Versteegen, Tim and Spory, Lea and Deckbar, Dorothee and Reiser, Lena and Bendig, Sonja and Bastian, Lorenz and Bozzetti, Cecilia and Beder, Thomas and Neumann, Martin and Brüggemann, Monika and Gökbuget, Nicola and Baldus, Claudia},
  title = {Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-06883-8}
}
Kostenlos starten →